Business Context and Reporting Period
Company: Synergy CHC Corp. (SNYR)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: Synergy is a consumer health care, beauty, and lifestyle company. Its portfolio is anchored by two marquee brands: FOCUSfactor (brain health supplements and energy RTDs) and Flat Tummy (weight management and wellness products). The company utilizes an asset-light model, partnering with third-party manufacturers. It recently completed an Initial Public Offering (IPO) in October 2024, listing on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Revenue | $34,834,243 | $42,777,633 |
| Gross Profit | $23,643,019 | $32,080,310 |
| Gross Margin | 68% | 75% |
| Net Income | $2,124,976 | $6,338,750 |
| EBITDA | $6,464,070 | $10,841,596 |
| Cash & Restricted Cash | $787,920 | $732,534 |
| Working Capital | ($1,124,601) Deficit | ($2,199,033) Deficit |
| Total Debt (Current + Long-Term) | $27,515,346 | $27,618,132 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by approximately 18.6% ($7.9 million) year-over-year. Management attributes this primarily to a rebranding and packaging upgrade for the FOCUSfactor line, which caused retailers to sell through existing inventory before restocking new packaging.
- Profitability Compression: Net income fell by 66.5% to $2.1 million. Gross margin contracted from 75% to 68% due to lower sales volume and a one-time supplier settlement gain in 2023 that reduced 2023 cost of sales.
- Operating Expenses: Selling and marketing expenses decreased by $2.2 million, and General and Administrative expenses decreased by $1.3 million, reflecting active expense management.
- Capital Structure: The company raised approximately $8.4 million in net proceeds from its October 2024 IPO. Concurrently, it restructured significant debt obligations with related parties (Knight Therapeutics), extending maturities to 2026 and consolidating various notes.
Outlook, Risks, and Contingencies
- Going Concern: Management evaluated conditions raising substantial doubt about the company's ability to continue as a going concern due to an accumulated deficit of $44.1 million and a working capital deficit. However, management concluded that the IPO proceeds, debt restructuring, and ability to raise additional capital alleviate these doubts for the next 12 months.
- Debt Covenants: The company is subject to strict financial covenants, including maintaining a minimum quarterly EBITDA of $1.25 million and FOCUSfactor trailing twelve-month net sales of at least $30 million. Failure to meet these could trigger default.
- Customer Concentration: The top two customers accounted for 73% of net revenue in 2024. The loss of a major retailer would materially impact operations.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and defined roles within finance functions. Remediation is ongoing.
- Strategic Initiatives: The company plans to expand FOCUSfactor Ready-to-Drink (RTD) products, enter new international markets (Taiwan, Mexico in 2025; Australia/Asia in 2026), and pursue strategic acquisitions.
Investor Verification Checklist
- Debt Maturity Wall: Verify the company's ability to meet $13.3 million in debt obligations due in 2025 and $15.8 million due in 2026, given the current cash position of ~$0.8 million.
- Covenant Compliance: Monitor quarterly EBITDA and FOCUSfactor sales figures to ensure compliance with the $1.25M EBITDA and $30M sales covenants.
- Rebranding Impact: Assess whether the revenue decline was temporary (inventory sell-through) or indicative of a longer-term demand shift for FOCUSfactor.
- Related Party Transactions: Review the terms of the consolidated debt with Knight Therapeutics and other related parties, noting the high interest rates and potential equity conversion features.
- Internal Control Remediation: Confirm the timeline and effectiveness of the remediation plan for the identified material weaknesses in financial reporting.